Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR 1 trial. The Phase I/II study is evaluating BI 3720931, a novel, first-in-class, inhaled gene therapy for the treatment of cystic fibrosis. With three decades of expertise in viral vector development and manufacturing, OXB will support the development of this potential treatment for CF, a genetic condition caused by mutations in the CFTR gene that affects more than 100,000 people worldwide. While CFTR modulators have provided treatment options for some patients, there remains a significant unmet need for 10-15% of people with CF due to mutation type or modulator intolerance. BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to address this need through a novel approach of inserting a functional copy of the CFTR gene in the DNA of airway epithelial cells.